NCT04116541View on ClinicalTrials.gov

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

PHASE2RecruitingINTERVENTIONAL
Enrollment

455

Participants

Timeline

Start Date

January 28, 2020

Primary Completion Date

February 28, 2026

Study Completion Date

November 30, 2026

Conditions
Malignant Solid Tumor
Interventions
DRUG

HDM201

HDM201 120mg, Every 3 weeks, Per os

DRUG

Ribociclib

Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os

DRUG

Cabozantinib

Cabozantinib, 60 mg /day, continuous, Per os

DRUG

Alectinib

Alectinib, 600mg twice daily, Per os

DRUG

Regorafenib

Regorafenib 160mg, once daily, 3 weeks on/1 week off, Per os

DRUG

Trametinib

Trametinib 2 mg/day, continuous, Per os

DRUG

Dabrafenib

Dabrafenib 150 mg twice daily, Per os

DRUG

Avapritinib

300 mg/day,continuous, Per os

Trial Locations (9)

13273

RECRUITING

Institut Paoli Calmettes, Marseille

14076

NOT_YET_RECRUITING

Centre François Baclesse, Caen

31059

RECRUITING

Institut Claudius Regaud, Toulouse

33076

RECRUITING

Institut Bergonié, Bordeaux

67033

RECRUITING

Institut de Cancérologie de Strasbourg, Strasbourg

69373

RECRUITING

Centre Léon Bérard, Lyon

75248

NOT_YET_RECRUITING

Institut Curie, Paris

94805

RECRUITING

Institut Gustave Roussy, Villejuif

06189

RECRUITING

Centre Antoine LACASSAGNE, Nice

All Listed Sponsors
lead

Centre Leon Berard

OTHER